Results 81 to 90 of about 4,014 (178)

HCV Genotype 6a Escape from and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models

, 2018
BACKGROUND & AIMS: Chronic liver diseases caused by hepatitis C virus (HCV) genotype 6 are prevalent in Asia, and millions of people require treatment with direct-acting antiviral regimens, such as NS5A inhibitor velpatasvir combined with the NS5B ...
Pham, Long, Jannie Pedersen, Yi-Ping Li, Ramirez Almeida, Santseharay, Li, Yiping, Pedersen, Jannie, Long V. Pham, Ulrik Fahnøe, Judith M. Gottwein, Fahnøe, Ulrik, Santseharay Ramirez, Bukh, Jens, Jens Bukh, Gottwein, Judith Margarete   +13 more
core   +1 more source

EXPERIENCE IN THE TREATMENT OF HEPATITIS C IN PREGNANT PATIENTS AT THE HEPATITIS CLINIC OF THE VERACRUZ HIGH SPECIALTY HOSPITAL

Annals of Hepatology
Introduction and Objectives: Currently, HCV treatment options during pregnancy are not well-defined. Typical clinical practice is to refer and link pregnant women for treatment after pregnancy and breastfeeding; however, in practice, very few have ...
Maria Teresa Guzmán Terrones, Eve Flynn Ferreira, Luis Del Carpio Orantes, Raúl Terrones Castro   +3 more
doaj   +1 more source

Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden

, 2019
Background: In both Russia and Sweden, the dominant hepatitis C virus (HCV) is genotype 1, but around one-third of patients have genotype 3 infection. For such countries, HCV genotype testing is recommended prior to therapy.
Abdurakhmanov, D., Brainard, D. M., Gankina, N., Kozhevnikova, G., Lu, S., Zhuravel, S., McNally, J., Lagging, Martin,, Chulanov, V., Romanova, S., Weiland, O., Svarovskaia, E. S., Zhdanov, K., Hyland, R. H., Ivashkin, V., Morozov, V., Isakov, V., Burnevich, E., Nurmukhametova, E., Bakulin, I.   +19 more
core   +1 more source

Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the treatment of chronic hepatitis C: the real-world data in China

BMC Gastroenterology
Background Sofosbuvir/Velpatasvir (Epclusa, ECS) is the first pan-genotype direct-acting antiviral agent (DAA) for hepatitis C virus (HCV) infection, and Danoprevir (DNV) is the first DAA developed by a Chinese local enterprise, which is suitable for ...
Yunjing Zhou, Minfeng Liang, Yiting Li, Xing Chen, Jie Yang, Honglian Bai, Yingzi Long, Xiaohong Zhang, Chaoshuang Lin   +8 more
doaj   +1 more source

Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir

, 2018
BACKGROUND & AIMS: Chronic infection with hepatitis C virus (HCV) has many hepatic and extrahepatic manifestations, measured by patient-reported outcomes (PROs).
Younossi, Issah, Reddy, K R, Bourliere, Marc, Jacobson, Ira, Stepanova, Maria, Flamm, Steven, Mann, Michael P, Gordon, Stuart C, Cooper, Curtis, Younossi, Zobair M, Kowdley, Kris, Hunt, Sharon, Zeuzem, Stefan   +12 more
core   +2 more sources

STABILITY-INDICATING RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF SOFOSBUVIR, VELPATASVIR, AND VOXILAPREVIR IN BULK AND TABLET DOSAGE FORMS [PDF]

, 2020
Objective: The present study was aimed to develop a novel, simple, rapid accurate and precise, stability-indicating reversed-phase high-performance liquid chromatography method for the simultaneous estimation of sofosbuvir, velpatasvir, and voxilaprevir ...
PADMINI M, VENKATA, D, GOWRI SANKAR
core   +1 more source

Enhanced dispersive solid phase extraction assisted by cloud point strategy prior to fluorometric determination of anti-hepatitis C drug velpatasvir in pharmaceutical tablets and body fluids

, 2018
Highly sensitive and selective solid phase extraction method combined with cloud point extraction strategy was developed for analysis of velpatasvir in its pharmaceutical tablets and biological fluids.
Mohamed M. El-Wekil, Ramadan Ali, Adel A. Marzouk, Hassan Refat H. Ali   +3 more
core   +1 more source

Eight-week treatment with sofosbuvir/velpatasvir may be effective in curing hepatitis C in children

Pediatria Polska
Sofosbuvir/velpatasvir (SOF/VEL) is a safe and effective regimen used for the treatment of chronic hepatitis C. The standard treatment duration is 12 weeks. There are no data available to support the shortened treatment.
Maria Pokorska-Śpiewak, Anna Dobrzeniecka, Magdalena Marczyńska   +2 more
doaj   +1 more source

Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir

, 2016
During a phase 3 study evaluating the combination of sofosbuvir-velpatasvir for 12 weeks in patients with genotype 1, 2, 4, 5, and 6 hepatitis C virus (HCV) infection, we enrolled a patient who was subsequently found to be infected with genotype 7 HCV ...
Svarovskaia, Evguenia, Moreno, Christophe, Schreiber, Jonas, John McNally, Krishna Chodavarapu, McNally, John, Christophe Moreno, Chodavarapu, Krishna, Evguenia Svarovskaia, Jonas Schreiber   +9 more
core   +1 more source

Direct-Acting Antiviral Agents in Prevention of Maternal–Fetal Transmission of Hepatitis C Virus in Pregnancy

Pathogens
Prior to the Food and Drug Administration approval of ledipaspavir/sofosbuvir (Harvoni®) in 2014, the treatment of hepatitis C was interferon plus or minus ribavirin.
Christopher Hartley, Trung Van, Wikrom Karnsakul   +2 more
doaj   +1 more source